@article{6f6c94914ff74ba28844abd062a2fb70,
title = "Interferon-gamma is quintessential for NOS2 and COX2 expression in ER- breast tumors that lead to poor outcome",
abstract = "A strong correlation between NOS2 and COX2 tumor expression and poor clinical outcomes in ER breast cancer has been established. However, the mechanisms of tumor induction of these enzymes are unclear. Analysis of The Cancer Genome Atlas (TCGA) revealed correlations between NOS2 and COX2 expression and Th1 cytokines. Herein, single-cell RNAseq analysis of TNBC cells shows potent NOS2 and COX2 induction by IFNγ combined with IL1β or TNFα. Given that IFNγ is secreted by cytolytic lymphocytes, which improve clinical outcomes, this role of IFNγ presents a dichotomy. To explore this conundrum, tumor NOS2, COX2, and CD8+ T cells were spatially analyzed in aggressive ER–, TNBC, and HER2 + breast tumors. High expression and clustering of NOS2-expressing tumor cells occurred at the tumor/stroma interface in the presence of stroma-restricted CD8+ T cells. High expression and clustering of COX2-expressing tumor cells extended into immune desert regions in the tumor core where CD8+ T cell penetration was limited or absent. Moreover, high NOS2-expressing tumor cells were proximal to areas with increased satellitosis, suggestive of cell clusters with a higher metastatic potential. Further in vitro experiments revealed that IFNγ + IL1β/TNFα increased the elongation and migration of treated tumor cells. This spatial analysis of the tumor microenvironment provides important insight into distinct neighborhoods where stroma-restricted CD8+ T cells exist proximal to NOS2-expressing tumor niches that could have increased metastatic potential.",
author = "Cheng, {Robert Y.S.} and Ridnour, {Lisa A.} and Wink, {Adelaide L.} and Gonzalez, {Ana L.} and Femino, {Elise L.} and Helene Rittscher and Veena Somasundaram and Heinz, {William F.} and Leandro Coutinho and Rangel, {M. Cristina} and Edmondson, {Elijah F.} and Donna Butcher and Kinders, {Robert J.} and Xiaoxian Li and Wong, {Stephen T.C.} and McVicar, {Daniel W.} and Anderson, {Stephen K.} and Milind Pore and Hewitt, {Stephen M.} and Billiar, {Timothy R.} and Glynn, {Sharon A.} and Chang, {Jenny C.} and Lockett, {Stephen J.} and Stefan Ambs and Wink, {David A.}",
note = "Funding Information: This project was funded in whole or in part with Federal funds from the Intramural Research Program of the NIH, National Cancer Institute, CCR, CIL (RYSC, LAR, ALG, ELF, HR, VS, RJK, SMH, DWM, SKA, SA, and DAW). This project has been funded in part with Federal funds from the Frederick National Laboratory for Cancer Research, National Institutes of Health, under contract HHSN261200800001E (ALW, WFH, MP, SKA, and SJL) and Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702 (SKA). This project was funded in part by S{\~a}o Paulo Research Foundation (FAPESP) grants 2018/08107-2 and 2021/14642-0 (MCR), NIH R01CA238727, NIH U01CA253553, and John S Dunn Research Foundation (STCW), NCI grant no. U54 CA210181, the Breast Cancer Research Foundation (BCRF), the Moran Foundation, Causes for a Cure, philanthropic support from M. Neal and R. Neal, and the Center for Drug Repositioning and Development Program (CREDO) (JCC), Science Foundation Ireland (SFI) grant number 17/CDA/4638, and a SFI and European Regional Development Fund (ERDF) grant number 13/RC/2073 (SAG). We wish to thank S{\~a}o Paulo Research Foundation (FAPESP) for sending students abroad (LC). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. Funding Information: This project was funded in whole or in part with Federal funds from the Intramural Research Program of the NIH, National Cancer Institute, CCR, CIL (RYSC, LAR, ALG, ELF, HR, VS, RJK, SMH, DWM, SKA, SA, and DAW). This project has been funded in part with Federal funds from the Frederick National Laboratory for Cancer Research, National Institutes of Health, under contract HHSN261200800001E (ALW, WFH, MP, SKA, and SJL) and Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702 (SKA). This project was funded in part by S{\~a}o Paulo Research Foundation (FAPESP) grants 2018/08107-2 and 2021/14642-0 (MCR), NIH R01CA238727, NIH U01CA253553, and John S Dunn Research Foundation (STCW), NCI grant no. U54 CA210181, the Breast Cancer Research Foundation (BCRF), the Moran Foundation, Causes for a Cure, philanthropic support from M. Neal and R. Neal, and the Center for Drug Repositioning and Development Program (CREDO) (JCC), Science Foundation Ireland (SFI) grant number 17/CDA/4638, and a SFI and European Regional Development Fund (ERDF) grant number 13/RC/2073 (SAG). We wish to thank S{\~a}o Paulo Research Foundation (FAPESP) for sending students abroad (LC). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. Publisher Copyright: {\textcopyright} 2023, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.",
year = "2023",
month = may,
doi = "10.1038/s41419-023-05834-9",
language = "English",
volume = "14",
journal = "Cell Death and Disease",
issn = "2041-4889",
number = "5",
}